1-甲基-2-四氢萘酮 | 4024-14-0

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪酮(含烯醇)
• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 1-甲基-2-四氢萘酮
• 中文别名: 1-甲基-2-四酮
• 英文名称: 1-methyl-2-tetralone
• 英文别名: 1-methyl-3,4-dihydronaphthalen-2(1H)-one；1-methyl-3,4-dihydro-1H-naphthalen-2-one
• CAS: 4024-14-0
• 化学式: C₁₁H₁₂O
• mdl: MFCD00001728
• 分子量: 160.216
• InChiKey: VGZQKUJGVYFKBP-UHFFFAOYSA-N

物化性质

• 沸点：
  261 °C (lit.)
• 密度：
  1.02 g/mL at 25 °C (lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29143900
• 储存条件：
  密封储存于阴凉、干燥的库房，冷藏温度为4°C。

SDS

Name:	1-Methyl-2-tetralone, tech., 90% Material Safety Data Sheet
Synonym:	None
CAS:	4024-14-0

Section 1 - Chemical Product MSDS Name: 1-Methyl-2-tetralone, tech., 90% Material Safety Data Sheet
Synonym: None

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
4024-14-0	1-Methyl-2-tetralone, tech., 90%	90%	223-690-7

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW The toxicological properties of this material have not been fully investigated. Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid contact with skin and eyes. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container. Keep refrigerated. (Store below 4C/39F.)

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels. Exposure Limits CAS# 4024-14-0: Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Liquid
Color: clear brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 105 - 107 deg C @ 2.00mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: > 112 deg C (> 233.60 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.0200g/cm3
Molecular Formula: C11H12O
Molecular Weight: 160.22

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Strong oxidzing agents
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 4024-14-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-2-tetralone, tech., 90% - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 4024-14-0: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 4024-14-0 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 4024-14-0 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 9/02/1997 Revision #2 Date: 3/18/2003 The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-2-四氢萘酮 在 2,3,4,5,6-pentahydroxy-hexanal 、 Bacillus megaterium glucose dehydrogenase 、 recombinant Hansenula polymorpha ketoreductase 、 nicotinamide adenine dinucleotide 作用下， 以 aq. phosphate buffer 为溶剂， 反应 24.0h， 生成 1-Methyl-1,2,3,4-tetrahydro-[2]naphthol
  参考文献：
  名称：

  多形汉逊酵母强大的酮还原酶在还原羰基化合物中的应用

  摘要：

  酶催化的酮的不对称还原是生产手性构件或合成生物活性化合物的前体的有吸引力的工具。扩大了多形汉逊酵母中健壮的酮还原酶（KRED）的表达，并将其用于将31种手性羰基化合物（脂族和芳族酮，二酮和β-酮​​酯）不对称还原为相应的光学纯羟基化合物。用纯化的重组KRED和NADP +循环葡萄糖脱氢酶（GDH，Bacillus megaterium）进行生物转化，二者均在大肠杆菌中过表达。BL21（DE3）。用于由高细胞密度培养实现乙基-2-甲基乙酰的生物转化KRED的最大活性为2499.7±234ü克-1 DCW和8.47±0.40 U·毫克-1 ê，分别。多形汉逊酵母的KRED是一种用途非常广泛的酶，具有广泛的底物特异性，并且对具有各种结构特征的羰基底物具有很高的活性。在这项研究中筛选的36种羰基底物中，KRED在31种情况下显示出活性，在大多数情况下具有高对映选择性。多态汉逊酵母KRED具有几种酮

  DOI：

  10.1016/j.mcat.2020.111364
• 作为产物：
  描述：

  1,2-epoxy-1-methyl-1,2,3,4-tetrahydro-naphthalene 在 indium(III) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 0.75h， 以87%的产率得到1-甲基-2-四氢萘酮
  参考文献：
  名称：

  Indium(III) Chloride-Promoted Rearrangement of Epoxides: A Selective Synthesis of Substituted Benzylic Aldehydes and Ketones

  摘要：

  A simple and efficient procedure for the rearrangement of substituted epoxides catalyzed by InCl3 has been developed. Aryl-substituted epoxides isomerize with complete regioselectivity to form a single carbonyl compound via cleavage of the benzylic C-O bond. The reactions are simple, fast, and high yielding. This procedure is very mild compared to those catalyzed with BF3 and other Lewis acids and compatible with several acid-sensitive functionalities. This protocol provides a highly selective synthesis of substituted benzylic aldehydes and ketones. However, rearrangement of alkyl-substituted epoxides is not very selective.

  DOI：

  10.1021/jo980793w

文献信息

• Enantioselective Decarboxylative Alkylation Reactions: Catalyst Development, Substrate Scope, and Mechanistic Studies
  作者：Douglas C. Behenna、Justin T. Mohr、Nathaniel H. Sherden、Smaranda C. Marinescu、Andrew M. Harned、Kousuke Tani、Masaki Seto、Sandy Ma、Zoltán Novák、Michael R. Krout、Ryan M. McFadden、Jennifer L. Roizen、John A. Enquist、David E. White、Samantha R. Levine、Krastina V. Petrova、Akihiko Iwashita、Scott C. Virgil、Brian M. Stoltz

  DOI：10.1002/chem.201003383

  日期：2011.12.9

  functions with nearly identical efficiency in terms of yield and enantioselectivity. Catalyst discovery and development, the optimization of reaction conditions, the exploration of reaction scope, and applications in target‐directed synthesis are reported. Experimental observations suggest that these alkylation reactions occur through an unusual inner‐sphere mechanism involving binding of the prochiral

  在钯配合物与各种膦恶唑啉 (PHOX) 配体的存在下，通过不稳定的前手性烯醇化亲核试剂对烯丙基和炔丙基亲电子试剂进行新颖的对映选择性烷基化来获得 α-季酮。三类烯醇化物前体获得了优异的产率和高对映体过量：烯醇碳酸酯、烯醇硅烷和外消旋 β-酮酯。这些底物类别中的每一种在产率和对映选择性方面都具有几乎相同的效率。报道了催化剂的发现和开发、反应条件的优化、反应范围的探索以及在靶向合成中的应用。实验观察表明，这些烷基化反应通过一种不寻常的内球机制发生，涉及前手性烯醇化亲核试剂直接与钯中心结合。
• NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP3305789A1

  公开（公告）日：2018-04-11

  The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3A R3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.

  本发明提供了一种具有抗病毒活性的新型化合物，特别是具有抑制HIV复制活性的化合物和含有该化合物的药物。该化合物由以下式表示： 其中A3为CR3A、CR3A R3B、N或NR3C；R3A、R3B、R4A和R4B分别独立地为氢原子、卤素、氰基、取代或未取代的烷基、取代或未取代的炔基，或取代或未取代的非芳香碳环烷基；R3C为氢原子、取代或未取代的烷基，或取代或未取代的非芳香碳环烷基；环T1为取代或未取代的含氮非芳香杂环；R1为氢原子、卤素、氰基，或取代或未取代的烷基；R2分别为取代或未取代的烷基或类似物；n为1或2；R3为取代或未取代的芳香碳环烷基或类似物；R4为氢原子或羧基保护基。
• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• Anti-infective agents
  申请人：Hutchinson K. Douglas

  公开号：US20050107364A1

  公开（公告）日：2005-05-19

  Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

  具有该公式的化合物是丙型肝炎（HCV）聚合酶抑制剂。还公开了一种用于抑制丙型肝炎（HCV）聚合酶的组成和方法，用于制造这些化合物的过程，以及在这些过程中使用的合成中间体。
• α-Hydroxylation of ketones: Osmium tetroxide/N-methylmorpholine-N-oxide oxidation of silyl enol ethers
  作者：J.P. McCormick、Witold Tomasik、Mark W. Johnson

  DOI：10.1016/s0040-4039(01)92501-8

  日期：1981.1

  Osmium tetroxide/N-methylmorpholine-N-oxide oxidation of silyl enol ethers, derived from ketones with either kinetic or thermodynamic regiochemical control, produces α-ketols in good to excellent yields.

  甲硅烷基烯醇醚的四氧化s / N-甲基吗啉-N-氧化物氧化反应是通过动力学或热力学区域化学控制的方式从酮中衍生出来的，可产生高至优异收率的α-酮醇。

表征谱图